Rahlfs Capital LLC Makes New Investment in Sanofi (NASDAQ:SNY)

Rahlfs Capital LLC acquired a new stake in Sanofi (NASDAQ:SNY) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 6,975 shares of the company’s stock, valued at approximately $336,000.

Other institutional investors also recently modified their holdings of the company. Abel Hall LLC increased its holdings in shares of Sanofi by 1.8% in the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock valued at $530,000 after purchasing an additional 194 shares during the last quarter. Providence Capital Advisors LLC boosted its holdings in shares of Sanofi by 0.4% during the 4th quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company’s stock worth $2,653,000 after buying an additional 201 shares during the period. Keudell Morrison Wealth Management grew its stake in Sanofi by 1.7% in the 4th quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock valued at $624,000 after buying an additional 217 shares during the last quarter. Bailard Inc. raised its holdings in Sanofi by 1.4% in the 4th quarter. Bailard Inc. now owns 16,359 shares of the company’s stock valued at $789,000 after acquiring an additional 220 shares during the period. Finally, Old Port Advisors lifted its position in Sanofi by 0.6% during the fourth quarter. Old Port Advisors now owns 36,704 shares of the company’s stock worth $1,770,000 after acquiring an additional 232 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on SNY. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Finally, The Goldman Sachs Group began coverage on shares of Sanofi in a research report on Friday, March 21st. They set a “neutral” rating and a $65.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $62.50.

Sanofi Trading Down 4.8 %

Shares of SNY stock opened at $51.98 on Friday. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $60.12. The stock’s fifty day moving average price is $55.37 and its two-hundred day moving average price is $52.71. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The company has a market cap of $131.92 billion, a PE ratio of 20.88, a P/E/G ratio of 1.01 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Equities analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.